Proteasome inhibitors: all 957 studies that test it
Page 9 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ LeukemiaCompletedNCT00511069Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid LeukemiaStatus unknownNCT00510939Phase 2
- Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaCompletedNCT00509379Phase 2
- Bortezomib and High-dose Melphalan at Myeloma RelapseStatus unknownNCT00508209Phase 2
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
- Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for MyelomaCompletedNCT00504634Phase 2
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaWithdrawnNCT00504101Phase 1
- Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer PatientsCompletedNCT00500422Phase 1
- Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 1
- Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2
- Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant MesotheliomaCompletedNCT00458913Phase 2
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- Velcade in Myelodysplastic Syndrome - Pilot StudyTerminatedNCT00440076Phase 2
- Velcade Plus ICE for Patients With Relapsed Classical Hodgkin LymphomaCompletedNCT00439361Phase 1
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple MyelomaStatus unknownNCT00438841Phase 2
- Bortezomib in Treating Patients With Advanced Myeloproliferative DisordersCompletedNCT00437086Early Phase 1
- The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)CompletedNCT00436059Phase 2
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed MyelomaStatus unknownNCT00431990Phase 1/2
- An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2
- Bevacizumab and Bortezomib in Patients With Advanced MalignancyCompletedNCT00428545Phase 1
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00428142Phase 2
- Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma PatientsCompletedNCT00417911Phase 3
- A Study of Bortezomib as Consolidation Therapy in Patients With Multiple MyelomaCompletedNCT00416273Phase 3
- Consolidation Therapy With Bortezomib in Elderly Patients With Multiple MyelomaCompletedNCT00416208Phase 3
- Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic SyndromesCompletedNCT00411905Phase 1/2
- Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT00411593Phase 1/2
- Bortezomib-Dexamethasone-Doxorubicin-StudyCompletedNCT00401804Phase 2
- Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma PatientsCompletedNCT00401011Phase 1/2
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory LymphomaCompletedNCT00396864Phase 1
- VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to TreatmentStatus unknownNCT00389701Phase 2
- Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.CompletedNCT00388635Phase 1/2
- Bortezomib and Topotecan in Treating Patients With Advanced Solid TumorsCompletedNCT00388089Phase 1
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseCompletedNCT00383474Phase 1
- Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLCompletedNCT00382954Phase 1
- Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMMStatus unknownNCT00378755Phase 2
- Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT00377052Phase 2
- Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell LymphomasCompletedNCT00374699Phase 1/2
- Velcade in MALT Lymphoma PatientsCompletedNCT00373906Phase 2
- Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal CarcinomaWithdrawnNCT00367718Phase 2
- Ph II CHOP+Velcade in Mediastinal LBCLTerminatedNCT00361621Phase 2
- A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma PatientsCompletedNCT00358020Phase 2
- A Study of ATN-224 and Bortezomib in Patients With Multiple MyelomaTerminatedNCT00352742Phase 1/2
- A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung CancerTerminatedNCT00346645Phase 2
- Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior TherapyCompletedNCT00343720Phase 2
- Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaTerminatedNCT00337506Phase 2
- Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseCompletedNCT00335348Phase 2
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00334932Phase 1/2
- Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00334438Phase 1
- A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer PatientsCompletedNCT00329589Phase 1
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant CandidatesCompletedNCT00320476Phase 2
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaStatus unknownNCT00319865Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung CancerWithdrawnNCT00313690Phase 1/2
- VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Status unknownNCT00311337Phase 2
- Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal CancerCompletedNCT00305734Phase 2
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple MyelomaCompletedNCT00291538Phase 1
- Bortezomib and Celecoxib in Treating Patients With Advanced Solid TumorsCompletedNCT00290680Phase 1
- Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaCompletedNCT00288041Phase 2
- Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell TransplantCompletedNCT00288028Phase 1
- A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung CancerTerminatedNCT00283634Phase 2
- Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal CancerCompletedNCT00280176Phase 1
- Study of Velcade and Thalidomide in Patients With MyelodysplasiaTerminatedNCT00271804Phase 1
- Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT00265928Phase 2
- Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT00261612Phase 2
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
- An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyCompletedNCT00216697Phase 2
- VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic TherapyTerminatedNCT00210392Phase 2
- VELCADE in MALT Lymphoma Pretreated With Prior Systemic TherapyCompletedNCT00210327Phase 2
- IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaCompletedNCT00200681Phase 3
- Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung CancerTerminatedNCT00200382Phase 2
- PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2CompletedNCT00199212Phase 1
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
- Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate CancerCompletedNCT00193232Phase 2
- Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)Status unknownNCT00184015Phase 1/2
- Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaTerminatedNCT00148018Phase 2
- Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaCompletedNCT00142129Phase 2
- A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell LymphomaTerminatedNCT00136591Phase 2
- Study of Bortezomib Combined With ACVBP in Peripheral T-cell LymphomaCompletedNCT00136565Phase 2
- Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaCompletedNCT00135187Not applicable
- Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With VelcadeCompletedNCT00129207Phase 1
- Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00118183Phase 2
- VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC FeaturesTerminatedNCT00117351Phase 2
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaCompletedNCT00116961Phase 2
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory PatientsCompletedNCT00111748Phase 3
- VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
- Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00107341Phase 2
- Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal CancerTerminatedNCT00106262Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach CancerTerminatedNCT00103103Phase 2
- Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00098982Phase 1
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2